Does mechanism of action always translate into efficacy?

What are the implications for your psoriasis patient's outcomes? A panel discussion with case study review. Understand the pathogenesis of plaque psoriasis, learn the development of targeted therapies for psoriasis, specifically IL-17A and IL-17F inhibitors, and understand the differences between the mechanism of action of biologic therapies. Particularly why the mechanism of action should be considered before prescribing a treatment for plaque psoriasis.

Presented by Dr Fiona Craig, Professor Brian Kirby, Dr Keith Wu and Dr Laura Savage.

Includes your reflective learning guide to download to obtain CPD accreditation.

Watch the full video to obtain CPD accreditation or watch in bite-size chunks by using the navigation below:



Full video



Case study 1

Case study 2

Orbit 360 enabled
Because we're in this together...

Report adverse events

Adverse events should be reported. Reporting forms and information can be found at and

Adverse events should also be reported to UCB Pharma Ltd Email: and

Feature requests

Help us to grow our resource the way you want it to grow.

Get in touch now

Date of preparation: February 2023